4,963 reports of this reaction
1.6% of all TREPROSTINIL reports
#14 most reported adverse reaction
FLUID RETENTION is the #14 most commonly reported adverse reaction for TREPROSTINIL, manufactured by United Therapeutics Corporation. There are 4,963 FDA adverse event reports linking TREPROSTINIL to FLUID RETENTION. This represents approximately 1.6% of all 313,927 adverse event reports for this drug.
TREPROSTINIL has an overall safety score of 85 out of 100. Patients taking TREPROSTINIL who experience fluid retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUID RETENTION is a less commonly reported adverse event for TREPROSTINIL, but still significant enough to appear in the safety profile.
In addition to fluid retention, the following adverse reactions have been reported for TREPROSTINIL:
The following drugs have also been linked to fluid retention in FDA adverse event reports:
FLUID RETENTION has been reported as an adverse event in 4,963 FDA reports for TREPROSTINIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUID RETENTION accounts for approximately 1.6% of all adverse event reports for TREPROSTINIL, making it a notable side effect.
If you experience fluid retention while taking TREPROSTINIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.